Answers are grounded in this paper and cite their sources.
Regulatory dendritic cell (DCregs)-based immunotherapy is a potential therapeutic tool for transplant rejection.We generated DCregs from murine induced pluripotent stem cells (iPSCs), which could remain in a ''stable immature stage'' even under strong stimulation.Harnessing this characteristic, we hypothesized that iPS-DCregs worked as a negative vaccine to generate regulatory T cells (Tregs), and induced donor-specific allograft acceptance.We immunized naive CBA (H-2K k ) mice with B6 (H-2K b ) iPS-DCregs and found that Tregs (CD4 + CD25 + FOXP3 + ) significantly increased in CBA splenocytes.Moreover, immunized CBA recipients permanently accepted B6 cardiac grafts in a donor-specific pattern.We demonstrated mechanistically that donor-type iPS-DCregs triggered transforming growth factor b1 secretion, under which the donor-antigen peptides directed naive CD4 + T cells to differentiate into donor-specific FOXP3 + Tregs instead of into effector T cells in vivo.These findings highlight the potential of iPS-DCregs as a key cell therapy resource in clinical transplantation.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: